Abstract:Count data regression modeling has received much attention in several science fields in which the Poisson, Negative binomial, and Zero-Inflated models are some of the primary regression techniques. Negative binomial regression is applied to modeling count variables, usually when they are over-dispersed. A Poisson distribution is also utilized for counting data where the mean is equal to the variance. This situation is often unrealistic since the distribution of counts will usually have a variance that is not equal to its mean. Modeling it as Poisson distributed leads to ignoring under- or overdispersion, depending on if the variance is smaller or larger than the mean. Also, situations with outcomes having a larger number of zeros such as RNASeq data require Zero-inflated models. Variable selection through shrinkage priors has been a popular method to address the curse of dimensionality and achieve the identification of significant variables. We present a unified Bayesian hierarchical framework that implements and compares shrinkage priors in negative-binomial and zero-inflated negative binomial regression models. The key feature is the representation of the likelihood by a Polya-Gamma data augmentation, which admits a natural integration with a family of shrinkage priors. We specifically focus on the Horseshoe, Dirichlet Laplace, and Double Pareto priors. Extensive simulation studies address the efficiency of the model and mean square errors are reported. Further, the models are applied to data sets such as the Covid-19 vaccine, and Covid-19 RNA-Seq data among others. The models are robust enough to address variable selection, and MSE decreases as the sample size increases, having lower errors in p>n cases. The noteworthy results showed that the adverse events of Covid-19 vaccines were dependent on age, recovery, medical history, and prior vaccination with a remarkable reduction in MSE of the fitted values. No. of publications of Ph.D. students were dependent on the no. of children, and the no. of articles in the last three years. The models are robust enough to conduct both variable selections and produce effective fit because of their high shrinkage property and applicability to a broad range of biometric and public health high dimensional problems.

Shrinkage priors for isotonic probability vectors and binary data modeling, with applications to dose–response modeling

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian Shrinkage Priors in Zero-Inflated and Negative Binomial Regression models with Real World Data Applications of COVID-19 Vaccine, and RNA-Seq

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Shrinkage estimation for dose-response modeling in phase II trials with multiple schedules

Quantitative Risk Assessment: Developing a Bayesian Approach to Dichotomous Dose-Response Uncertainty

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Benchmark Dose Analysis via Nonparametric Regression Modeling

Bayesian Regression Using a Prior on the Model Fit: The R2-D2 Shrinkage Prior

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

Bayesian Nonparametric Risk Assessment in Developmental Toxicity Studies with Ordinal Responses

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian Nonparametric Model for Heterogeneous Treatment Effects With Zero‐Inflated Data

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

A Bayesian Nonparametric Model for Zero-Inflated Outcomes: Prediction, Clustering, and Causal Estimation

Identifying treatment effect heterogeneity in dose-finding trials using Bayesian hierarchical models

Bayesian Variable Selection for Mixed Effects Model with Shrinkage Prior.